These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [New treatments for cancer of the prostate]. AMIEL C Vie Med; 1959 Apr; 40(4):337 passim. PubMed ID: 13659813 [No Abstract] [Full Text] [Related]
4. Effect of endocrine ablative surgery on the urinary excretion of 17-ketosteroids in advanced cancer of the breast. HOBKIRK R J Clin Endocrinol Metab; 1958 Jun; 18(6):636-42. PubMed ID: 13539175 [No Abstract] [Full Text] [Related]
7. Proton irradiation of the pituitary. LAWRENCE JH Cancer; 1957; 10(4):795-8. PubMed ID: 13472621 [No Abstract] [Full Text] [Related]
8. Implantation of radioactive material into the pituitary for the control of prostatic cancer: an interim review. FERGUSSON JD Br J Urol; 1957 Sep; 29(3):215-21. PubMed ID: 13471943 [No Abstract] [Full Text] [Related]
9. Destruction of the hypophysis with radioactive colloidal chromic phosphate in cancer of the prostate. JOHNSON PC; WEST KM; RUTLEDGE BJ J Neurosurg; 1958 Sep; 15(5):519-27. PubMed ID: 13576195 [No Abstract] [Full Text] [Related]
10. Bioavailability, distribution and pharmacokinetics of diethylstilbestrol converted from diethylstilbestrol diphosphate in patients with prostatic cancer. Nakamura K Hiroshima J Med Sci; 1986 Dec; 35(4):325-38. PubMed ID: 3570844 [No Abstract] [Full Text] [Related]
11. [High-dose intravenous diethylstilbestrol diphosphate therapy for hormone refractory prostate cancer]. Honda M; Umeda H; Yoshida K Nihon Rinsho; 1998 Aug; 56(8):2145-9. PubMed ID: 9750524 [No Abstract] [Full Text] [Related]
12. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis. Prout GR; Kliman B; Daly JJ; MacLaughlin RA; Griffin PP; Young HH Urology; 1976 Feb; 7(2):148-55. PubMed ID: 1246784 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of estrogen-resistant forms of cancer of the prostate]. Marinbakh EB; Ar'e VM Urol Nefrol (Mosk); 1974; 39(4):68-74. PubMed ID: 4606039 [No Abstract] [Full Text] [Related]
14. Pituitary necrosis due to implants of radioactive gold and yttrium. YOUNG S Lancet; 1957 Mar; 272(6968):548-51. PubMed ID: 13407057 [No Abstract] [Full Text] [Related]
15. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Citrin DL; Kies MS; Wallemark CB; Khandekar J; Kaplan E; Camacho F; Lind R Cancer; 1985 Aug; 56(3):457-60. PubMed ID: 4005808 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells. Schulz P; Bauer HW; Brade WP; Keller A; Fittler F Cancer Res; 1988 May; 48(10):2867-70. PubMed ID: 2834049 [TBL] [Abstract][Full Text] [Related]
17. [Scintigraphic control of bone metastases of prostatic cancer treated with cytonal and cyclophosphamide]. Grossmann J; Weiss M; Deckart H; Raatzsch H Radiobiol Radiother (Berl); 1988; 29(6):736-8. PubMed ID: 3253797 [No Abstract] [Full Text] [Related]
18. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. Maatman TJ; Gupta MK; Montie JE J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712 [TBL] [Abstract][Full Text] [Related]
19. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron]. Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097 [TBL] [Abstract][Full Text] [Related]
20. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Sugihara A; Maeda O; Tsuji M; Tsujimura T; Nakata Y; Akedo H; Kotake T; Terada N Oncol Rep; 1998; 5(6):1389-94. PubMed ID: 9769374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]